RVNC - Revance Therapeutics GAAP EPS of -$1.82 misses by $0.78 revenue of $49.9M beats by $4.8M
- Revance Therapeutics press release ( NASDAQ: RVNC ): Q4 GAAP EPS of -$1.82 misses by $0.78 .
- Revenue of $49.9M (+92.3% Y/Y) beats by $4.8M .
- Sales primarily increased due to sales of the RHA Collection and sales of DAXXIFY® during the PrevU program.
- DAXXIFY Q4 PrevU revenue of $11.0 million, with commercial launch to begin late March 2023.
For further details see:
Revance Therapeutics GAAP EPS of -$1.82 misses by $0.78, revenue of $49.9M beats by $4.8M